Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Potential Colorectal Cancer Biomarker Discovered At Guangzhou Medical University

This article was originally published in PharmAsia News

Executive Summary

A research team led by Xu Xuehu at the Third Hospital Affiliated Guangzhou Medical University found that miRNA (a small molecular nucleic acid) is closely correlated with the incidence and development of colorectal cancer.

A research team led by Xu Xuehu at the Third Hospital Affiliated Guangzhou Medical University found that miRNA (a small molecular nucleic acid) is closely correlated with the incidence and development of colorectal cancer. Among all others, 17 miRNAs have the potential to be used as a biomarker for clinical screening. If the biomarker of miRNA works, the accurate determination of its concentration will help to detect tumors at least ten months faster than other methods. (Click Here For More - Chinese Language)

"Guangzhou Physicians Found Potential New Biomarker Of Colorectal Cancer" - health.people.com.cn (6/2/2014)

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC087498

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel